1. Structural Biology and Molecular Biophysics

ER-luminal [Ca2+] regulation of InsP3 receptor gating mediated by an ER-luminal peripheral Ca2+-binding protein

  1. Horia Vais
  2. Min Wang
  3. Karthik Mallilankaraman
  4. Riley Payne
  5. Chris McKennan
  6. Jeffrey T Lock
  7. Lynn A Spruce
  8. Carly Fiest
  9. Matthew Y Chan
  10. Ian Parker
  11. Steven H Seeholzer
  12. J Kevin Foskett  Is a corresponding author
  13. Don-On Daniel Mak
  1. University of Pennsylvania, United States
  2. University of Pittsburgh, United States
  3. University of California, Irvine, United States
  4. Children's hospital of Philadelphia, United States
https://doi.org/10.7554/eLife.53531
Share this article
Cite this article
  1. Horia Vais
  2. Min Wang
  3. Karthik Mallilankaraman
  4. Riley Payne
  5. Chris McKennan
  6. Jeffrey T Lock
  7. Lynn A Spruce
  8. Carly Fiest
  9. Matthew Y Chan
  10. Ian Parker
  11. Steven H Seeholzer
  12. J Kevin Foskett
  13. Don-On Daniel Mak
(2020)
ER-luminal [Ca2+] regulation of InsP3 receptor gating mediated by an ER-luminal peripheral Ca2+-binding protein
eLife 9:e53531.
https://doi.org/10.7554/eLife.53531
  2. Download BibTeX
  3. Download .RIS

Abstract

Modulating cytoplasmic Ca2+ concentration ([Ca2+]i) by endoplasmic reticulum (ER)-localized inositol 1,4,5-trisphosphate receptor (InsP3R) Ca2+-release channels is a universal signaling pathway that regulates numerous cell-physiological processes. Whereas much is known regarding regulation of InsP3R activity by cytoplasmic ligands and processes, its regulation by ER-luminal Ca2+ concentration ([Ca2+]ER) is poorly understood and controversial. We discovered that the InsP3R is regulated by a peripheral membrane-associated ER-luminal protein that strongly inhibits the channel in the presence of high, physiological [Ca2+]ER. The widely-expressed Ca2+-binding protein annexin A1 (ANXA1) is present in the nuclear envelope lumen and, through interaction with a luminal region of the channel, can modify high-[Ca2+]ER inhibition of InsP3R activity. Genetic knockdown of ANXA1 expression enhanced global and local elementary InsP3-mediated Ca2+ signaling events. Thus, [Ca2+]ER is a major regulator of InsP3R channel activity and InsP3R-mediated [Ca2+]i signaling in cells by controlling an interaction of the channel with a peripheral membrane-associated Ca2+-binding protein, likely ANXA1.

Data availability

All data generated and analyzed are included in the manuscript and supporting files.

Article and author information

Author details

  1. Horia Vais

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Min Wang

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Karthik Mallilankaraman

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9492-9050

  4. Riley Payne

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Chris McKennan

    Department of Statistics, University of Pittsburgh, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Jeffrey T Lock

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1522-3189

  7. Lynn A Spruce

    Proteomics Core, Children's hospital of Philadelphia, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Carly Fiest

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1162-712X

  9. Matthew Y Chan

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Ian Parker

    Department of Physiology and Biophysics, University of California, Irvine, Irvine, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Steven H Seeholzer

    Proteomics Core, Children's hospital of Philadelphia, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. J Kevin Foskett

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    For correspondence
    foskett@pennmedicine.upenn.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8854-0268

  13. Don-On Daniel Mak

    Department of Physiology, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (R37GM56328)

  • J Kevin Foskett

National Institutes of Health (R01GM114042)

  • Don-On Daniel Mak

National Institutes of Health (GM048071)

  • Ian Parker

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Vais et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,690
    views
  • 239
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Horia Vais
  2. Min Wang
  3. Karthik Mallilankaraman
  4. Riley Payne
  5. Chris McKennan
  6. Jeffrey T Lock
  7. Lynn A Spruce
  8. Carly Fiest
  9. Matthew Y Chan
  10. Ian Parker
  11. Steven H Seeholzer
  12. J Kevin Foskett
  13. Don-On Daniel Mak
(2020)
ER-luminal [Ca2+] regulation of InsP3 receptor gating mediated by an ER-luminal peripheral Ca2+-binding protein
eLife 9:e53531.
https://doi.org/10.7554/eLife.53531

Share this article

https://doi.org/10.7554/eLife.53531

Categories and tags

Further reading

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics

    The co-receptor Tetraspanin12 directly captures Norrin to promote ligand-specific β-catenin signaling

    Elise S Bruguera, Jacob P Mahoney, William I Weis
    Research Article

    Wnt/β-catenin signaling directs animal development and tissue renewal in a tightly controlled, cell- and tissue-specific manner. In the mammalian central nervous system, the atypical ligand Norrin controls angiogenesis and maintenance of the blood-brain barrier and blood-retina barrier through the Wnt/β-catenin pathway. Like Wnt, Norrin activates signaling by binding and heterodimerizing the receptors Frizzled (Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), leading to membrane recruitment of the intracellular transducer Dishevelled (Dvl) and ultimately stabilizing the transcriptional coactivator β-catenin. Unlike Wnt, the cystine knot ligand Norrin only signals through Fzd4 and additionally requires the co-receptor Tetraspanin12 (Tspan12); however, the mechanism underlying Tspan12-mediated signal enhancement is unclear. It has been proposed that Tspan12 integrates into the Norrin-Fzd4 complex to enhance Norrin-Fzd4 affinity or otherwise allosterically modulate Fzd4 signaling. Here, we measure direct, high-affinity binding between purified Norrin and Tspan12 in a lipid environment and use AlphaFold models to interrogate this interaction interface. We find that Tspan12 and Fzd4 can simultaneously bind Norrin and that a pre-formed Tspan12/Fzd4 heterodimer, as well as cells co-expressing Tspan12 and Fzd4, more efficiently capture low concentrations of Norrin than Fzd4 alone. We also show that Tspan12 competes with both heparan sulfate proteoglycans and LRP6 for Norrin binding and that Tspan12 does not impact Fzd4-Dvl affinity in the presence or absence of Norrin. Our findings suggest that Tspan12 does not allosterically enhance Fzd4 binding to Norrin or Dvl, but instead functions to directly capture Norrin upstream of signaling.

    1. Structural Biology and Molecular Biophysics

    The known unknowns of the Hsp90 chaperone

    Laura-Marie Silbermann, Benjamin Vermeer ... Katarzyna Tych
    Review Article

    Molecular chaperones are vital proteins that maintain protein homeostasis by assisting in protein folding, activation, degradation, and stress protection. Among them, heat-shock protein 90 (Hsp90) stands out as an essential proteostasis hub in eukaryotes, chaperoning hundreds of ‘clients’ (substrates). After decades of research, several ‘known unknowns’ about the molecular function of Hsp90 remain unanswered, hampering rational drug design for the treatment of cancers, neurodegenerative, and other diseases. We highlight three fundamental open questions, reviewing the current state of the field for each, and discuss new opportunities, including single-molecule technologies, to answer the known unknowns of the Hsp90 chaperone.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics

    Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

    Raji E Joseph, Thomas E Wales ... Amy H Andreotti
    Research Advance

    Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors including Acalabrutinib, Zanubrutinib, Tirabrutinib, and Pirtobrutinib have been clinically approved. All are covalent active site inhibitors, with the exception of the reversible active site inhibitor Pirtobrutinib. The large number of available inhibitors for the BTK target creates challenges in choosing the most appropriate BTKi for treatment. Side-by-side comparisons in CLL have shown that different inhibitors may differ in their treatment efficacy. Moreover, the nature of the resistance mutations that arise in patients appears to depend on the specific BTKi administered. We have previously shown that Ibrutinib binding to the kinase active site causes unanticipated long-range effects on the global conformation of BTK (Joseph et al., 2020). Here, we show that binding of each of the five approved BTKi to the kinase active site brings about distinct allosteric changes that alter the conformational equilibrium of full-length BTK. Additionally, we provide an explanation for the resistance mutation bias observed in CLL patients treated with different BTKi and characterize the mechanism of action of two common resistance mutations: BTK T474I and L528W.